Mirum's LIVMARLI gets positive CHMP opinion for PFIC; EC decision in Q3 2024

Mirum Pharmaceuticals, Inc.

CHMP adopted positive opinion for LIVMARLI (maralixibat) to treat PFIC in patients aged 3 months and older.
CHMP concluded LIVMARLI provides significant clinical benefit vs already-approved PFIC treatment.
COMP recommended maintaining Orphan Drug Designation for LIVMARLI in PFIC.
European Commission decision on marketing authorization expected in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.